Replimune Group stock
REPLNASDAQReplimune Group, Inc., HealthcareISIN US76029N1063
43Score 43 out of 100, Weak
Price and trend
79 / 100
Price history
+143% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 122% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 85).
The price is 5.6% below its 52-week high. Largest decline in 8 years: 97% (December 2020 to April 2026).
Chart figures for advanced users
- SMA 50$14.63
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.92
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)85
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.70
- The lowest closing price of the last twelve months.
- Resistance$23.28
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Replimune Group, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $2.31B, is number 119 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 43 out of 100 (Weak): rank 511 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $268.89M, financial debt $111.59M.
Weaknesses
- DilutionShare count up 101% since 2021.Capital allocation 18
- Volatile share priceVolatility 187% a year over the last 12 months.Stability 48
- Loss-makingLoss of $313.94M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 42 to 43.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Feb 2027in 82 days
- Last reported
- 28 Oct 2026EPS reported −$0.54 (expected −$0.78)above expectations
Analyst estimates
Analysts have raised their 2028 earnings estimate by 28.8% since 15 Oct 2026.
- Earnings per share
- −$2.31+20.1%
- Revenue
- $34.37M−15.4%
- Earnings per share
- −$1.36+28.8%
- Revenue
- $177.08M−0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 8 insiders sold, $2.15M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Slattery Joseph PSale
9 Nov 2026, Board
- Shares
- 5,200
- Price
- $21.80
- Value
- $113,360
- Dhingra KapilSale
2 Nov 2026, Board
- Shares
- 21,500
- Price
- $19.00
- Value
- $408,500
- Hill Emily LuisaSale
17 Aug 2026, Chief Financial Officer
- Shares
- 9,256
- Price
- $14.28
- Value
- $132,176
Show 11 more
- Patel SushilSale
10 Aug 2026, Chief Executive Officer
- Shares
- 39,341
- Price
- $12.97
- Value
- $510,253
- Hill Emily LuisaSale
10 Aug 2026, Chief Financial Officer
- Shares
- 11,448
- Price
- $12.97
- Value
- $148,481
- Xynos KonstantinosSale
10 Aug 2026, Chief Medical Officer
- Shares
- 11,447
- Price
- $12.97
- Value
- $148,468
- Schwendenman AndrewSale
10 Aug 2026, Chief Accounting Officer
- Shares
- 7,632
- Price
- $12.97
- Value
- $98,987
- Sarchi ChristopherSale
1 Jun 2026, Chief Commercial Officer
- Shares
- 12,000
- Price
- $9.24
- Value
- $110,880
- Xynos KonstantinosSale
18 May 2026, Chief Medical Officer
- Shares
- 14,023
- Price
- $5.08
- Value
- $71,237
- Schwendenman AndrewSale
18 May 2026, Chief Accounting Officer
- Shares
- 7,894
- Price
- $5.08
- Value
- $40,102
- Sarchi ChristopherSale
18 May 2026, Chief Commercial Officer
- Shares
- 8,626
- Price
- $5.08
- Value
- $43,820
- Astley-Sparke PhilipSale
18 May 2026, Board
- Shares
- 17,657
- Price
- $5.08
- Value
- $89,698
- Patel SushilSale
18 May 2026, Chief Executive Officer
- Shares
- 37,324
- Price
- $5.08
- Value
- $189,606
- Hill Emily LuisaSale
18 May 2026, Chief Financial Officer
- Shares
- 7,812
- Price
- $5.08
- Value
- $39,685
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Replimune Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Palvella TherapeuticsPVLA $2.4B43
- Celldex TherapeuticsCLDX $2.37B36
- Trevi TherapeuticsTRVI $2.37B41
- BiohavenBHVN $2.29B43
- SepternaSEPN $2.27B48
- ImmunomeIMNM $2.25B37
- Vir BiotechnologyVIR $2.25B52
- Recursion PharmaceuticalsRXRX $2.24B39
ETFs that hold Replimune Group
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.12% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.